CSGALNACT1

CSGALNACT1 (CSGalNAcT-1/ChGn-1) is a Golgi-type N-acetylgalactosaminyltransferase that initiates chondroitin sulfate (CS) chain biosynthesis by transferring GalNAc in a beta-1,4 linkage onto the GlcA-Gal-Gal-Xyl GAG-protein linker tetrasaccharide; ectopic expression shifts glycosaminoglycan output from heparan sulfate toward chondroitin sulfate, confirming its role in committing chains to the CS pathway in vivo (PMID:12446672). This catalytic activity is functionally critical: point mutations at residues such as Ser-126, Asn-264, Pro-384, and Asp-432 abolish or sharply reduce GalNAc-transferase activity and disrupt glycosaminoglycan composition in patient fibroblasts (PMID:27599773, PMID:26806424, PMID:31705726), and biallelic loss-of-function variants in humans cause a skeletal dysplasia (PMID:27599773, PMID:31705726). In the CNS, CSGalNAcT1 supplies CS chains for perineuronal nets, and its loss reduces brain CS by roughly half without affecting the aggrecan core protein, altering ocular dominance plasticity and social behavior (PMID:28982363, PMID:28987564), while also generating the inhibitory CS barrier that limits axon regeneration after spinal cord injury (PMID:28987564). The CS chains produced by CSGalNAcT1 are enriched in non-sulfated O-unit disaccharides, which bind tau seeds and monomers with high affinity and promote tau capture, cellular uptake, and aggregation (PMID:41996943).

1. 2002 High

   Established the founding biochemical activity: whether CSGalNAcT-1 initiates CS chain assembly was answered by showing it adds the first GalNAc to the linker tetrasaccharide and redirects GAG output toward chondroitin sulfate.

   Evidence In vitro GalNAc-transferase assay on linker substrates plus CHO transfection with GAG composition analysis on a syndecan-4/FGF-1 chimera

   PMID:12446672

   Open questions at the time

   • Structural basis of substrate recognition not resolved
   • Relative contribution versus CSGalNAcT-2 in vivo not addressed
2. 2016 Medium

   Connected enzyme activity to disease and pinpointed catalytic residues: missense mutations (p.Pro384Arg; p.S126L) reduce or abolish GalNAc-transferase activity, establishing that the catalytic function is required for CS biosynthesis and skeletal development.

   Evidence Biochemical activity assays of recombinant/cell-expressed mutant proteins, clinical genetics, and fibroblast proteoglycan analysis

   PMID:26806424 PMID:27599773

   Open questions at the time

   • Single-lab activity measurements
   • Structural explanation for residue criticality not provided
3. 2017 High

   Defined the CNS requirement: knockout mice resolved whether CSGalNAcT1 is needed for CS in perineuronal nets and for plasticity, showing ~50% brain CS loss, depleted PNN CS, and altered ocular dominance plasticity and behavior.

   Evidence Knockout mouse with CS quantification, PNN immunohistochemistry, and behavioral testing

   PMID:28982363 PMID:28987564

   Open questions at the time

   • Mechanism linking CS loss to specific behavioral phenotypes not dissected
   • Cell-type-specific contributions not isolated
4. 2017 Medium

   Linked the enzyme to injury repair: knockout mice showed extensive axon regeneration after spinal cord injury, establishing that CSGalNAcT1-synthesized CS forms an inhibitory barrier to CNS axon growth.

   Evidence Spinal cord injury in knockout mice with axon regeneration assessment

   PMID:28987564

   Open questions at the time

   • No orthogonal mechanistic confirmation of the inhibitory mechanism
   • Functional recovery outcomes not detailed
5. 2019 Medium

   Broadened the disease/biochemistry link: additional missense variants (p.Asp432Tyr, p.Asn264Ser) reduce activity and disrupt chondroitin, dermatan, and heparan sulfate moieties in patient cells, confirming loss of activity perturbs glycosaminoglycan biosynthesis broadly.

   Evidence Recombinant mutant activity assays, fibroblast disaccharide analysis, and trio-exome sequencing

   PMID:31705726

   Open questions at the time

   • Single-lab study
   • Genotype-phenotype correlation across patients not established
6. 2026 Medium

   Defined a disease-relevant downstream consequence: O-unit-enriched CS produced by CSGALNACT1 binds tau with high affinity and promotes its capture, uptake, and aggregation, linking the enzyme's chain output to tau pathology.

   Evidence Overexpression in Neuro2a cells with tau seed uptake assay, CS disaccharide analysis, in vitro tau aggregation, and CS-tau binding affinity measurement

   PMID:41996943

   Open questions at the time

   • Single-lab in vitro/cell evidence not validated in vivo
   • Relevance to human tauopathy progression not established

• How CSGalNAcT1 activity is regulated, how O-unit-enriched chain composition is controlled, and the structural basis of its substrate specificity remain open.
• No structural model in the corpus
• Regulation of chain sulfation pattern uncharacterized
• Functional division of labor with CSGalNAcT-2 unresolved